ImmunityBio Inc. [NASDAQ: IBRX] plunged by -$0.04 during the normal trading session on Tuesday and reaching a high of $1.67 during the day while it closed the day at $1.54. The company report on February 16, 2023 that ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU.
A positive difference in physical function in responders versus non-responders was noted.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The study indicates a favorable risk/benefit ratio and quality of life following N-803 plus BCG is comparable to BCG alone.
ImmunityBio Inc. stock has also loss -13.97% of its value over the past 7 days. However, IBRX stock has declined by -63.85% in the 3 months of the year. Over the past six months meanwhile, it has lost -69.92% and lost -69.63% year-on date.
The market cap for IBRX stock reached $683.42 million, with 403.64 million shares outstanding and 83.44 million shares in the current float. Compared to the average trading volume of 3.51M shares, IBRX reached a trading volume of 3901002 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about ImmunityBio Inc. [IBRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IBRX shares is $9.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IBRX stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for ImmunityBio Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 03, 2022.
The Average True Range (ATR) for ImmunityBio Inc. is set at 0.23, with the Price to Sales ratio for IBRX stock in the period of the last 12 months amounting to 3417.11.
IBRX stock trade performance evaluation
ImmunityBio Inc. [IBRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -13.97. With this latest performance, IBRX shares gained by 6.94% in over the last four-week period, additionally sinking by -69.92% over the last 6 months – not to mention a drop of -71.11% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IBRX stock in for the last two-week period is set at 36.03, with the RSI for the last a single of trading hit 37.21, and the three-weeks RSI is set at 34.44 for ImmunityBio Inc. [IBRX]. The present Moving Average for the last 50 days of trading for this stock 2.4445, while it was recorded at 1.6220 for the last single week of trading, and 4.2977 for the last 200 days.
ImmunityBio Inc. [IBRX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and ImmunityBio Inc. [IBRX] shares currently have an operating margin of -146090.42 and a Gross Margin at -9980.00. ImmunityBio Inc.’s Net Margin is presently recorded at -173569.58.
Additionally, IBRX Total Debt to Total Capital is recorded at 260.91, with Total Debt to Total Assets ending up at 200.17.
Reflecting on the efficiency of the workforce at the company, ImmunityBio Inc. [IBRX] managed to generate an average of -$574,575 per employee. Receivables Turnover for the company is 0.15 with a Total Asset Turnover recorded at a value of 0.00.ImmunityBio Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.30 and a Current Ratio set at 0.30.
Earnings per share (EPS) analysis for ImmunityBio Inc. [IBRX] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IBRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for ImmunityBio Inc. go to -1.70%.
ImmunityBio Inc. [IBRX]: Insider Ownership positions
There are presently around $84 million, or 10.30% of IBRX stock, in the hands of institutional investors. The top three institutional holders of IBRX stocks are: VANGUARD GROUP INC with ownership of 8,255,246, which is approximately 2.175% of the company’s market cap and around 72.71% of the total institutional ownership; CVI HOLDINGS, LLC, holding 7,609,166 shares of the stock with an approximate value of $12.02 million in IBRX stocks shares; and BLACKROCK INC., currently with $11.09 million in IBRX stock with ownership of nearly 12.915% of the company’s market capitalization.
Positions in ImmunityBio Inc. stocks held by institutional investors increased at the end of Thursday and at the time of the Thursday reporting period, where 71 institutional holders increased their position in ImmunityBio Inc. [NASDAQ:IBRX] by around 16,702,354 shares. Additionally, 51 investors decreased positions by around 3,162,482 shares, while 30 investors held positions by with 33,131,548 shares. The mentioned changes placed institutional holdings at 52,996,384 shares, according to the latest SEC report filing. IBRX stock had 27 new institutional investments in for a total of 11,021,236 shares, while 11 institutional investors sold positions of 1,660,413 shares during the same period.